Biohaven Is A Clinical Stage Biopharmaceutical Company Based In New Havenconnecticutfounded In 2013It Focuses On Discoveringdevelopingand Commercializing Therapies For Neurologicalneuropsychiatricimmunologicaland Oncological Disordersthe Company Aims To Address Diseases With Limited Treatment Options Through Innovative Science And Efficient Clinical Execution Biohaven Specializes In Clinical Stage Drug Developmentwith A Strong Emphasis On Lateand Early Stage Programsits Key Products Include Nurtecaodta Cgrp Receptor Antagonist For Migraine Treatment And Preventionand Zavzpreta Ca Nasal Spray For Acute Migraine Reliefthe Company Also Has A Pipeline Of Candidates Targeting Conditions Such As Amyotrophic Lateral Sclerosisalsand Obsessive Compulsive Disorderocd Biohaven Holds 68 Patents Related To Its Therapeutic Innovationswhich Include Small Molecule Approaches For Rare Diseases And Oncologywith A Commitment To Advancing Its Portfoliobiohaven Actively Engages With Healthcare Providers And Researchers To Enhance Therapeutic Access For Patientsparticularly Those Suffering From Neurological And Rare Diseases
